[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"kidney-transplant-failure\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:kidney-transplant-failure":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100499824","phase-4-can-dapagliflozin-preserve-structure-and-function-in-transplanted-kidneys-100499824",false,"NCT05788276","Can Dapagliflozin Preserve Structure and Function in Transplanted Kidneys?","DEAKTransplant","Inclusion Criteria:\n\n* Renal transplant recipients transplanted 6 weeks earlier at Oslo University hospital (OUH) Rikshospitalet.\n* Age 18-75 years.\n* Able to comply with the medical treatment on their own.\n* Calcineurin inhibitor trough concentrations in accordance with individual therapeutic range and standard dose prednisolone and mycophenolate mofetil over the last 2 weeks.\n* Estimated GFR ≥25 mL\u002Fmin\u002F1.73 m2.\n\nExclusion Criteria:\n\n* Type 1 diabetes\n* Rejection episodes of the kidney graft prior to randomization.\n* Ongoing infectious disease or intermittent causes affecting renal function, e.g., obstructive lymphocele.\n* Malnutrition.\n* Urosepsis less than 1 year prior to randomization.\n* Participants with a known hypersensitivity to dapagliflozin or any of the excipients of the product.\n* For women only - currently pregnant","ALL","18 Years","75 Years",{"count":20,"type":21},330,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The goal of this clinical trial is to look at the effect of SGLT2 (Sodium glucose transporter 2) inhibition in patients receiving a kidney-transplant 6 weeks earlier at Oslo University hospital. Rikshospitalet. Investigators will search for answers along three pathways: Can SGLT2 inhibitor 1) preserve glomerular filtration rate (GFR), 2) reduce interstitial fibrosis in the kidney, and 3) favorably improve metabolic risk factors for graft failure such as visceral obesity, glucose intolerance and high blood pressure? The participants (N=330) will be randomized to either dapagliflozin 10 mg or placebo o.d. in a blinded fashion. Researchers will than use kidney transplant biopsies, measured GFR, blood pressure sampling, glucose tolerance test (OGTT), dual-energy X-ray absorptiometry (DXA scan) and estimated GFR from the two groups in comparison, to evaluate the effect treatment. The participants will be followed for a total of 3 years.",[27,28,29],"Kidney Transplant; Complications","Kidney Transplant Failure","Renal Failure",[31,32,33,34],"Kidney","Transplantation","SGLT2","Renal function","RECRUITING","2025-03-26",{"date":38,"type":39},"2025-04-01","ACTUAL",{"date":41,"type":39},"2023-05-02",{"date":43,"type":21},"2028-06",{"name":45,"class":46},"Oslo University Hospital","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":47},"100577786","prevent-allosensitization-in-patients-who-have-failed-a-first-renal-transplant-part-100577786","NCT06802822","Prevent Allosensitization in Patients Who Have Failed a First Renal Transplant (PART)","The PART PILOT STUDY: a Pilot Study to Inform the Feasibility of a Definitive Prospective Interventional Study to Prevent Allosensitization in Patients Who Have Failed a First Renal Transplant","Inclusion Criteria:\n\n* Patients ≥ 19 years old with a failed first kidney transplant and planned dialysis start date.\n\nExclusion Criteria:\n\n* Previous extra-renal organ transplant, or more than one previous kidney transplant\n* Not prescribed tacrolimus or cyclosporine at the time of transplant failure\n* Active infection or cancer that precludes IMSN, or non-transplant indication to continue IMSN\n* Receipt of an HLA identical donor transplant kidney with low risk for sensitization\n* Patients without archived donor samples to determine eplet mismatch and donor specific antibodies\n* Planned nephrectomy of the failed allograft\n* Graft survival of ≤ 12 months due to rejection\n* Designated as non-repeat transplant candidates by their transplant center or cPRA ≥ 90% at the time of enrollment in whom further increase in cPRA may permanently preclude repeat transplantation\n* Planned living donor transplant or planned move away from study center","19 Years",{"count":57,"type":21},96,[59],"NA","Kidney transplant is often the best treatment for people with kidney failure, but transplanted kidneys don't always last a lifetime. Many transplanted kidneys fail within 12 years, leaving patients needing dialysis or another transplant. One major issue is something called \"allosensitization,\" which happens when the immune system attacks the donated kidney due to foreign markers on the kidney. This makes it harder to match a patient with another donor kidney in the future.\n\nTo try to prevent this, patients are given immunosuppressants (drugs that weaken the immune system) after a transplant to stop the immune system from attacking the new kidney. However, after a kidney transplant fails and patients return to dialysis, there's no clear evidence that continuing immunosuppressants helps prevent allosensitization. Plus, these drugs have serious risks, including infections, heart disease, and even cancer.\n\nThe PART study is a pilot study designed to explore whether continuing immunosuppression after a failed transplant for two years (instead of stopping after six months) can lower the risk of allosensitization and whether it is safe to do so. This pilot will also gather data that will be used for a larger trial in the future.\n\nThe study will be done at 12 different research centers, and around 96 patients will be enrolled in the pilot trial. The ultimate goal is to better understand if continuing immunosuppressants after transplant failure can make a difference, and whether it's safe enough to proceed to a larger, more definitive trial.",[62,28,63],"Kidney Transplant","Immunosuppresion",[65,66,67,68],"kidney transplant","kidney transplant failure","immunosuppression","sensitization","NOT_YET_RECRUITING","2025-01-24",{"date":72,"type":39},"2025-01-31",{"date":74,"type":21},"2025-01",{"date":76,"type":21},"2027-12",{"name":78,"class":46},"University of British Columbia"]